Reuters · Healthcare · 2026-09-04
Ionis, Novartis' key experimental heart drug fails in late-stage trial
Ionis Pharmaceuticals and partner Novartis' experimental drug to lower high levels of a cholesterol-carrying particle in heart patients failed in a late-stage trial, the companies said on Friday. Ionis, Novartis' key experimental heart drug fails in late-stage trial.
Why it matters. This failure impacts the development pipeline of major pharmaceutical companies and delays new treatment options for patients with high cholesterol-carrying particles.
Read original on Reuters Get the app
Licensed summary · LicensedSummary
Related briefs
- MDMA To Treat PTSD? Why The Party-Drug Will Now Be Prescribed To Patients With
- Needle found in one-year-old’s body, family alleges medical negligence at
- Always Need to Pee? These Everyday Habits Could Be Triggering an Overactive
- Saina Nehwal undertakes a ’29 day plank’ challenge — expert notes core benefits
- World Beard Day 2026: 7 Easy Beard Care Tips To Keep Your Beard Clean